Skip to main content

Advertisement

SpringerLink
Log in

A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Although alpha-fetoprotein (AFP) is a golden diagnostic marker for hepatocellular carcinoma (HCC), its value is debatable. Differentiation between primary and secondary hepatocarcinomas (HC) relying on AFP is confusing, does not exceed 20 % in the later. To find alternative markers other than AFP to differentiate between primary and secondary HC from colorectal carcinoma (CRC) and breast (BC) and lung cancers (LC), 60 individuals were recruited: group 1, healthy volunteers; group 2, with primary; and group 3, with secondary HC. Carcinoembryonic antigen (CEA), total glycosaminoglycans (TGAGs), total sialic acid (TSA), free glucosamine (FGA), leucine aminopeptidase (LAP), 5′-nucleotidase (5′-NU) activities, and AFP were estimated in sera, in addition to liver histology. CEA, TGAGs, TSA, and FGA were elevated in secondary HC among CRC primary cancers, while LAP, 5′-NU activities, and AFP were elevated in primary HCC. We concluded that a new panel can be used to differentiate primary from secondary HC better than AFP, speculating the primary cancer. AFP, LAP, and 5′-NU predominated in primary, while CEA, TGAGs, TSA, and FGA, in secondary HC. Elevation of 5′-NU, LAP, TGAGs, TSA, and FGA to CEA indicated that primary source of HC is CRC. Association of TGAGs, TSA, and FGA only to CEA indicated that the primary cancer is breast. Elevation of TGAGs, TSA, and FGA, with other normal parameters, indicated that the primary cancer is lung. A guiding table is recommended in the oncology laboratory, for management and follow-up, and having more expected level of sensitivity than AFP.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Abbruzzese JL, Abbruzzese MC, Lenzi R, Hess KR, Raber MN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13:2094–103.

    Article  CAS  PubMed  Google Scholar 

  2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005;9:191–211.

    Article  PubMed  Google Scholar 

  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  4. IuS T. Detection of embryo-specific alpha-globulin in the blood serum of a patient with primary liver cancer. Vopr Med Khim. 1964;10:90–1.

    Google Scholar 

  5. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol. 2000;31:302–8.

    Article  CAS  PubMed  Google Scholar 

  6. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol. 2006;12:1175–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology. 2008;134:1752–63.

    Article  PubMed  Google Scholar 

  8. Zhu K, Dai Z, Pan Q, Wang Z, Yang GH, Yu L, et al. Metadherin promotes hepatocellular carcinoma metastasis through induction of epithelial-mesenchymal transition. Clin Cancer Res. 2011;17:7294–302.

    Article  CAS  PubMed  Google Scholar 

  9. Wee A, Nilsson B. Highly well differentiated hepatocellular carcinoma and benign hepatocellular lesions. Can they be distinguished on fine needle aspiration biopsy? Acta Cytol. 2003;47:16–26.

    Article  PubMed  Google Scholar 

  10. Schima W, Kulinna C, Langenberger H, Ba-Ssalamah A. Liver metastases of colorectal cancer: US, CT or MR? Cancer Imaging. 2005;5 Spec No A:S149–156.

    Article  PubMed  Google Scholar 

  11. Abdel-Hamid N, Farid M, Eldemeri A, Atwa M, Anbar N. Pro-angiogenic mediators as targets for chemotherapy of colorectal carcinoma. Am J Med Med Sci. 2011;1:7–14.

    Article  Google Scholar 

  12. Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology. 2011;54:1987–97.

    Article  PubMed  Google Scholar 

  13. Beard DB, Haskell CM. Carcinoembryonic antigen in breast cancer. Clinical review. Am J Med. 1986;80:241–5.

    Article  CAS  PubMed  Google Scholar 

  14. Haskell CM, Buchegger F, Schreyer M, Carrel S, Mach JP. Monoclonal antibodies to carcinoembryonic antigen: ionic strength as a factor in the selection of antibodies for immunoscintigraphy. Cancer Res. 1983;43:3857–64.

    CAS  PubMed  Google Scholar 

  15. Sardi A, Agnone CM, Nieroda CA, Mojzisik C, Hinkle G, Ferrara P, et al. Radioimmunoguided surgery in recurrent colorectal cancer: the role of carcinoembryonic antigen, computerized tomography, and physical examination. South Med J. 1989;82:1235–44.

    Article  CAS  PubMed  Google Scholar 

  16. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med. 1991;115:623–38.

    Article  CAS  PubMed  Google Scholar 

  17. Lee HS, Chung YH, Kim CY. Specificities of serum alpha-fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma. Hepatology. 1991;14:68–72.

    Article  CAS  PubMed  Google Scholar 

  18. Sato Y, Nakata K, Kato Y, Shima M, Ishii N, Koji T, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med. 1993;328:1802–6.

    Article  CAS  PubMed  Google Scholar 

  19. Wu JC, Lee SD, Hsiao KJ, Wang SS, Chou P, Tsao D, et al. Mass screening of primary hepatocellular carcinoma by alpha-fetoprotein in a rural area of Taiwan—a dried blood spot method. Liver. 1988;8:100–4.

    Article  CAS  PubMed  Google Scholar 

  20. Oses JP, Cardoso CM, Germano RA, Kirst IB, Rucker B, Furstenau CR, et al. Soluble NTPDase: an additional system of nucleotide hydrolysis in rat blood serum. Life Sci. 2004;74:3275–84.

    Article  PubMed  Google Scholar 

  21. Yegutkin GG. Kinetic analysis of enzymatic hydrolysis of ATP in human and rat blood serum. Biochemistry (Mosc). 1997;62:619–22.

    CAS  Google Scholar 

  22. Kuang Y, Salem N, Wang F, Schomisch SJ, Chandramouli V, Lee Z. A colorimetric assay method to measure acetyl-CoA synthetase activity: application to woodchuck model of hepatitis virus-induced hepatocellular carcinoma. J Biochem Biophys Methods. 2007;70:649–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Martinek RG, Berger L, Broida D. Simplified estimation of leucine aminopeptidase (LAP) activity. Clin Chem. 1964;10:1087–97.

    CAS  PubMed  Google Scholar 

  24. Gornall AG, Bardawill CJ, David MM. Determination of serum proteins by means of the biuret reaction. J Biol Chem. 1949;177:751–66.

    CAS  PubMed  Google Scholar 

  25. Elson L, Morgan WT. A colorimetric method for the determination of glucosamine and chondrosamine. Biochem J. 1933;27:1824–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Warren L. The thiobarbituric acid assay of sialic acids. J Biol Chem. 1959;234:1971–5.

    CAS  PubMed  Google Scholar 

  27. Gold E. A simple spectrophotometric method for estimating glycosaminoglycan concentrations. Anal Biochem. 1979;99:183–8.

    Article  CAS  PubMed  Google Scholar 

  28. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003;23:1747–53.

    CAS  PubMed  Google Scholar 

  29. Taketa K, Okada S, Win N, Hlaing NK, Wind KM. Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. Acta Med Okayama. 2002;56:317–20.

    PubMed  Google Scholar 

  30. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25:3866–84.

    Article  CAS  PubMed  Google Scholar 

  31. Ward J. New MR, techniques for the detection of liver metastases. Cancer Imaging. 2006;6:33–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Fu K, Kobayashi A, Saito N, Sano Y, Kato S, Ikematsu H, et al. Alpha-fetoprotein-producing colon cancer with atypical bulky lymph node metastasis. World J Gastroenterol. 2006;12:7715–6.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Bae JS, Park SJ, Park KB, Paik SY, Ryu JK, Choi CK, et al. Acute exacerbation of hepatitis in liver cirrhosis with very high levels of alpha-fetoprotein but no occurrence of hepatocellular carcinoma. Korean J Intern Med. 2005;20:80–5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Yao FY. Dramatic reduction of the alpha-fetoprotein level after lamivudine treatment of patients with chronic hepatitis B virus infection and cirrhosis. J Clin Gastroenterol. 2003;36:440–2.

    Article  CAS  PubMed  Google Scholar 

  35. Tibbetts LM, Doremus CM, Tzanakakis GN, Vezeridis MP. Liver metastases with 10 human colon carcinoma cell lines in nude mice and association with carcinoembryonic antigen production. Cancer. 1993;71:315–21.

    Article  CAS  PubMed  Google Scholar 

  36. Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem. 2001;47:624–30.

    CAS  PubMed  Google Scholar 

  37. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79:1443–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Robertson JF, Jaeger W, Syzmendera JJ, Selby C, Coleman R, Howell A, et al. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. European Group for Serum Tumour Markers in Breast Cancer. Eur J Cancer. 1999;35:47–53.

    Article  CAS  PubMed  Google Scholar 

  39. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001;7:2357–62.

    CAS  PubMed  Google Scholar 

  40. Jonsson PE, Bengtsson G, Carlsson G, Jonson G, Tryding N. Value of serum-5-nucleotidase, alkaline phosphatase and gamma-glutamyl transferase for prediction of liver metastases preoperatively in colorectal cancer. Acta Chir Scand. 1984;150:419–23.

    CAS  PubMed  Google Scholar 

  41. Pohl AL, Reiner G, Kolb R, Sauermann G, Moser KV, Spona J. Enzyme activities in human breast tumor cells and sera. Cancer Detect Prev. 1985;8:57–66.

    CAS  PubMed  Google Scholar 

  42. Pilar M, Ramirez-Exposito MJ, Duenas B, Dolores Mayas M, Jesus Garcia M, De la Chica S, et al. Insulin-regulated aminopeptidase/placental leucil aminopeptidase (IRAP/P-lAP) and angiotensin IV-forming activities are modified in serum of rats with breast cancer induced by N-methyl-nitrosourea. Anticancer Res. 2006;26:1011–4.

    Google Scholar 

  43. Yamazaki T, Akada T, Niizeki O, Suzuki T, Miyashita H, Sato Y. Puromycin-insensitive leucyl-specific aminopeptidase (PILSAP) binds and catalyzes PDK1, allowing VEGF-stimulated activation of S6K for endothelial cell proliferation and angiogenesis. Blood. 2004;104:2345–52.

    Article  CAS  PubMed  Google Scholar 

  44. Cooper EH, Turner R, Steele L, Neville AM, Mackay AM. The contribution of serum enzymes and carcinoembryonic antigen to the early diagnosis of metastatic colorectal cancer. Br J Cancer. 1975;31:111–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Ghadge MS, Sirsat AV, Bhansali MS, Desouza LJ, Jagannath P. Leucine amino peptidase a better indicator of carcinoma of liver, biliary tract and pancreas. Indian J Clin Biochem. 2001;16:60–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Kalathas D, Theocharis DA, Bounias D, Kyriakopoulou D, Papageorgakopoulou N, Stavropoulos MS, et al. Alterations of glycosaminoglycan disaccharide content and composition in colorectal cancer: structural and expressional studies. Oncol Rep. 2009;22:369–75.

    CAS  PubMed  Google Scholar 

  47. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol. 2000;156:529–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Vavetsi R, Bonovas S, Polizou P, Papanastasopoulou C, Dougekou G, Sitaras NM. The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study. BMC Pulm Med. 2009;9:9.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase—partners in osteolytic tumor growth and metastasis. Matrix Biol. 2004;23:341–52.

    Article  CAS  PubMed  Google Scholar 

  50. Elenius V, Gotte M, Reizes O, Elenius K, Bernfield M. Inhibition by the soluble syndecan-1 ectodomains delays wound repair in mice overexpressing syndecan-1. J Biol Chem. 2004;279:41928–35.

    Article  CAS  PubMed  Google Scholar 

  51. Topuz E, Tore G, Bilge N, Aldemir O, Kural N, Kinay M, et al. Neuraminic acid (NANA) in the serum as an indicator in breast cancer. Strahlenther Onkol. 1986;162:187–90.

    CAS  PubMed  Google Scholar 

  52. Miyata M, Kambe M, Tajima O, Moriya S, Sawaki H, Hotta H, et al. Membrane sialidase NEU3 is highly expressed in human melanoma cells promoting cell growth with minimal changes in the composition of gangliosides. Cancer Sci. 2011;102:2139–49.

    Article  CAS  PubMed  Google Scholar 

  53. Hogan-Ryan A, Fennelly JJ, Jones M, Cantwell B, Duffy MJ. Serum sialic acid and CEA concentrations in human breast cancer. Br J Cancer. 1980;41:587–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Basoglu M, Atamanalp SS, Yildirgan MI, Aydinli B, Ozturk G, Akcay F, et al. Correlation between the serum values of soluble intercellular adhesion molecule-1 and total sialic acid levels in patients with breast cancer. Eur Surg Res. 2007;39:136–40.

    Article  CAS  PubMed  Google Scholar 

  55. Painbeni T, Gamelin E, Cailleux A, Le Bouil A, Boisdron-Celle M, Daver A, et al. Plasma sialic acid as a marker of the effect of the treatment on metastatic colorectal cancer. Eur J Cancer. 1997;33:2216–20.

    Article  CAS  PubMed  Google Scholar 

  56. de los Reyes GC, Koda RT, Lien EJ. Glucosamine and chondroitin sulfates in the treatment of osteoarthritis: a survey. Prog Drug Res. 2000;55:81–103.

    Article  CAS  PubMed  Google Scholar 

  57. Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am. 1999;25:379–95.

    Article  CAS  PubMed  Google Scholar 

  58. Werle B, Kraft C, Lah TT, Kos J, Schanzenbacher U, Kayser K, et al. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer. 2000;89:2282–91.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None

Compliance with ethical standards

We got approval from Minia University research and ethics committee and got written consents for all the participated patients.

Author information

Authors and Affiliations

  1. Biochemistry Department, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt

    Nabil Mohie Abdel-Hamid

  2. Biochemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt

    M. M. Abouzied, M. H. Nazmy & M. A. Fawzy

  3. Oncology Department, College of Medicine, Minia University, Minia, Egypt

    A. S. Gerges

Authors
  1. Nabil Mohie Abdel-Hamid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. M. Abouzied
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. H. Nazmy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. A. Fawzy
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. S. Gerges
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nabil Mohie Abdel-Hamid.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Abdel-Hamid, N.M., Abouzied, M.M., Nazmy, M.H. et al. A suggested guiding panel of seromarkers for efficient discrimination between primary and secondary human hepatocarcinoma. Tumor Biol. 37, 2539–2546 (2016). https://doi.org/10.1007/s13277-015-4025-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4025-7

Keywords

Search

Navigation